Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Clinical trial NCT05554393 · RECRUITING
Trial details
- NCT number
- NCT05554393
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-13
- Primary completion
- 2027-12-31
- Enrollment
- 153
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.